Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.

2019 full-year results and update on activities

Dowload PDF File (351Ko)

Theranexus annouces the success of its phase 2 trial for THN102 in Parkinson's patients

Dowload PDF File (351Ko)

THERANEXUS announces the clinical results of its phase 1b study demonstrating the extended pharmacological profile of its drug candidate THN201 compared to donepezil

Download PDF File (381 Ko)

THERANEXUS and Beyond Batten Disease Foundation (BBDF) announce the signing of a worldwide exclusive license for Batten disease drug candidate BBDF-101

Download PDF File (363 Ko)

THERANEXUS reports cash position as of September 30th 2019

Download PDF File (285 Ko)